GF:MRK MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders. It also provides over-the-counter products to relieve muscle, joint, and back pain, as well as cold and headaches; probiotic nutritional supplements; vitamin C; and various products with vitamins, minerals, and nutrients that support women's health during pregnancy, nursing, and menopause under the Neurobion, Bion, Femibion, Floratil, Nasivin, Seven Seas, Apaisyl, Cebion, Sangobion, Kytta, Sedalmerck, Vigantoletten, and Doloneurobion brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of chemical and biotechnological origin drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, photovoltaics, printing technology, coatings, plastics, cosmetics, and food industries. MERCK Kommanditgesellschaft auf Aktien has strategic alliances with Pfizer Inc. and Baylor College of Medicine; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to co-develop and co-commercialize CAR-T cancer therapies; and collaborations with F-star and Cancer Research Technology. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol MKGAF.

This company has ADRs that trade in the U.S. as the symbol MKKGY.This company has cross-listed shares that trade in the U.S. as the symbol MKGAF.

165.60 EUR
As of 03/21/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Germany
Country of incorporation:  Germany
IPO date:  12/04/2006
Stock exchange:    Frankfurt Stock Exchange
Exchange country:   Germany
Market cap:   73,879,822,336 EUR
Current dividend yield:   1.13%
Sedol:      4741844

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy